

## Variant: *NM\_001754.4(RUNX1):c.508+3delA*

Version: 1.0

[CA248618](#)

[14466 \(ClinVar\)](#)

**Gene:** RUNX1 ([HGNC:861](#))

**Condition:** hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome ([MONDO:0011071](#))

**Inheritance Mode:** Autosomal dominant inheritance

**UUID:** d7a48ae9-bd50-426d-bb9f-589c53013a9b

**Approved on:** 2019-08-01

**Published on:** 2019-08-02

### *HGVS expressions*

**NM\_001754.4:c.508+3delA**

- NM\_001754.4(RUNX1):c.508+3delA
- NC\_000021.9:g.34880554del
- CM000683.2:g.34880554del
- NC\_000021.8:g.36252851del
- CM000683.1:g.36252851del
- NC\_000021.7:g.35174721del
- NG\_011402.2:g.1109158del
- ENST00000675419.1:c.508+3del
- ENST00000300305.7:c.508+3del
- ENST00000344691.8:c.427+3del
- ENST00000358356.9:c.427+3del
- ENST00000399237.6:c.472+3del
- ENST00000399240.5:c.427+3del
- ENST00000437180.5:c.508+3del
- ENST00000482318.5:c.\*98+3del
- NM\_001001890.2:c.427+3del
- NM\_001122607.1:c.427+3del
- NM\_001754.4:c.508+3del
- NM\_001001890.3:c.427+3del
- NM\_001122607.2:c.427+3del
- NM\_001754.5:c.508+3del

**Pathogenic**

**Met criteria codes** 5

- PS4\_Supporting
- PP1\_Strong
- PP3
- PS3
- PM2

**Not Met criteria codes** 21

- BA1
- PVS1
- BP5
- BP7
- BP4
- BP3
- BP1
- BP2
- BS1
- BS4
- BS3
- BS2
- PP2
- PP4
- PM1
- PM3
- PM5
- PM4
- PS1
- PS2
- PM6

**Evidence Links** 1

### Expert Panel

[Myeloid Malignancy VCEP](#)




### Criteria Specification Information

[Criteria Specifications for this VCEP](#)

**Myeloid Malignancy VCEP**


There is RT-PCR assay evidence demonstrating that the NM\_001754.4:c.508+3delA variant creates a cryptic splice donor site that is used and results in a frameshift and introduction of premature termination codon (PS3; PMID: 11830488). This variant was found to co-segregate with disease in multiple affected family members, with eight meioses observed in one family (PP1\_Strong; PMID: 11830488). It is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2). This intronic variant (in intron 5) is located in reference to the exon at positions +3 for donor splice site and have a predicted decrease in the score of the canonical splice site by at least 75% (measured by both MES and SSF). This variant has been reported in one proband meeting at least one of the RUNX1-phenotypic criteria (PS4\_Supporting; PMID: 11830488). In summary, this variant meets criteria to be classified as pathogenic. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PS3, PP1\_Strong, PM2, PP3, PS4\_Supporting.

**Met criteria codes**

<b>PS4_Supporting</b>	<b>✓</b>	One family with FPD/AML. <hr/> One family with FPD/AML. <a href="#">PubMed:11830488</a> 
<b>PP1_Strong</b>	<b>✓</b>	8 meioses in a family with FPD/AML. <hr/> 8 meioses in a family with FPD/AML. <a href="#">PubMed:11830488</a> 
<b>PP3</b>	<b>✓</b>	Intronic variant (in introns 5) located in reference to exon at positions +3 for donor splice site and have a predicted decrease in the score of the canonical splice site by at least 75% (measured by both MES and SSF)
<b>PS3</b>	<b>✓</b>	RT-PCR assay demonstrates the use of a cryptic splice donor site resulted in frameshift, PMID: 11830488. <hr/> A 1-bp deletion in the splice donor site of intron 5 of the RUNX1 gene. The novel transcript resulting from use of a cryptic donor site resulted in frameshift after amino acid 135, addition of 41 unrelated residues, and termination at codon 177 (Arg135fsTer177). <a href="#">PubMed:11830488</a> 
<b>PM2</b>	<b>✓</b>	The variant is absent from all population databases.

**Not Met criteria codes**

<b>BA1</b>	<b>✗</b>	No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
<b>PVS1</b>	<b>✗</b>	No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
<b>BP5</b>	<b>✗</b>	No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline

<b>BP7</b>	✘	No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
<b>BP4</b>	✘	No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
<b>BP3</b>	✘	No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
<b>BP1</b>	✘	No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
<b>BP2</b>	✘	No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
<b>BS1</b>	✘	No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
<b>BS4</b>	✘	8 meioses in a family with FPD/AML. <a href="#">PubMed:11830488</a> 
<b>BS3</b>	✘	No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
<b>BS2</b>	✘	No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
<b>PP2</b>	✘	No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
<b>PP4</b>	✘	No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
<b>PM1</b>	✘	No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
<b>PM3</b>	✘	No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
<b>PM5</b>	✘	No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
<b>PM4</b>	✘	No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline

<b>PS1</b>	✘	No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
<b>PS2</b>	✘	No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
<b>PM6</b>	✘	No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline

Curation History [↗](#)

Showing 1 to 1 of 1 rows

	▼	▼
--	---	---

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.